Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000423819
Ethics application status
Not yet submitted
Date submitted
2/04/2012
Date registered
16/04/2012
Date last updated
16/04/2012
Type of registration
Prospectively registered

Titles & IDs
Public title
Effects of Rapid Administration of Iron Polymaltose in Patients with Anaemia, Under General Anaesthesia for Routine Surgery. “The RAPID Trial”
Scientific title
An evaluation of adverse events and haemodynamic instability resulting from the rapid administration of iron polymaltose infusion in the operating department, in patients with iron deficiency anaemia under general anaesthesia for elective surgical procedures.
Secondary ID [1] 280267 0
ANZCA regKey 13/022
Universal Trial Number (UTN)
Trial acronym
RAPID
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Peri-operative Anaemia 286215 0
Condition category
Condition code
Blood 286430 286430 0 0
Anaemia
Anaesthesiology 286503 286503 0 0
Other anaesthesiology

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
We aim to recruit 100 patients with iron deficiency anaemia or iron deficiency who are scheduled to undergo general anaesthesia for an elective surgical procedure. They will receive an intravenous iron polymaltose infusion over a 10 min period intra operatively, immediately following induction of anaesthesia during a period of haemodynamic stability. The dose given will be determined by the patients body weight and severity of anaemia (as dictated by a previously validated algorithm) up to a maximum dose of 1g. We will collect data on any adverse effects and change in blood pressure over this time and for 15 minutes following the infusion. Changes in blood pressure occuring as a result of the infusion will be compared to the decrease in blood pressure seen at the commencement of the patient's anaesthetic.
Intervention code [1] 284617 0
Treatment: Drugs
Comparator / control treatment
The patients will act as their own control; blood pressure changes secondary to anaesthetic will serve as control measurements against which changes secondary to the intervention are compared.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 286873 0
Incidence of significant hypotension (i.e. systolic BP <80mmhg) and tachycardia (heart rate >100).

This will be measured using standard non-invasive blood pressure devices and a 3 lead ECG. All of this equipment is standardised anaesthetic monitoring in place for any general anaesthetic.
Timepoint [1] 286873 0
Haemodynamic data collection (BP and Heart Rate) at 5 minute intervals commencing before induction of anaesthesia and for 15 minutes following induction of anaesthesia.

Haemodynamic data collection (BP and Heart Rate) at 5 minute intervals commencing before commencement of iron polymaltose during the infusion (10 minutes) and for 15 minutes after completeion of the infusion.
Secondary outcome [1] 296876 0
Other adverse events.
Headache, nausea, flushing hypotension, muscle cramps.
Timepoint [1] 296876 0
Questionnaire at 2 hours post operatively. This is a general questionnaire asking about any other symptoms that may or may not be present. It is not intended to use a specific previously validated tool to assess this.

Eligibility
Key inclusion criteria
Iron deficiency anaemia defined as Hb < 120g/L if female or Hb < 130g/L if male with ferritin < 100 or Iron deficiency alone, defined as ferritin < 30

Elective surgery / procedure requiring general anaesthesia
Minimum age
18 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Pregnancy

Iron overload (haemochromatosis or haemosiderosis) or ferritin > 100

Clinically significant renal or liver disease

Chronic polyarthritis

Active infection

Allergy / intolerance to iron polymaltose

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients will be recruited from the routine anaesthetic preassesment clinic which they universlly attend preoperatively. Patients who are found to have iron deficiency anaemia at this preoperative visit will be approached to join the study. All patients wil receive the same treatment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/07/2012
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
100
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 285029 0
Charities/Societies/Foundations
Name [1] 285029 0
Australian and New Zealand College of Anaesthetists
Country [1] 285029 0
Australia
Primary sponsor type
Hospital
Name
Fremantle Hospital
Address
Alma Street
Fremantle POBOX 480
West Australia
6160
Country
Australia
Secondary sponsor category [1] 283893 0
None
Name [1] 283893 0
Address [1] 283893 0
Country [1] 283893 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 287034 0
Fremantle Hospital
Ethics committee address [1] 287034 0
Ethics committee country [1] 287034 0
Date submitted for ethics approval [1] 287034 0
01/05/2012
Approval date [1] 287034 0
Ethics approval number [1] 287034 0

Summary
Brief summary
Aim
We aim to show that giving intravenous iron polymaltose over 10 minutes to patients who are under general anaesthesia is convenient, safe and not associated with a significant incidence of low blood pressure or other adverse effects.

Background
- Anaemia and iron deficiency are very common in surgical patients. A recent audit at KEMH, the tertiary womens hospital in WA, showed that 18% of women were anaemic prior to their gynaecological surgery. In patients undergoing surgery anaemia has been linked with an increased risk of needing a blood transfusion, slower recovery from surgery and an increase in postoperative complications. Patients often suffer from decreased energy, fatigue and poor ability to concentrate, all of which will affect their quality of life.
- Iron polymaltose is an intravenous iron medication commonly used to correct anaemia and iron deficiency. It has been used in Australia for over 40 years, has a very good safety record and about 4-500 women a year receive iron polymaltose at KEMH currently. It is usually administered as a slow infusion over 2 - 3 hours in a general ward setting. Common adverse effects can include headache, nausea, flushing, low blood pressure and muscle cramps all of which are not as relevant to patients whilst they are under general anaesthesia. Serious adverse events such as anaphylaxis are extremely rare and are not related to the speed at which iron polymaltose is given.
- Oral iron tablets are not effective in many patients for a number of reasons. It would labour intensive, expensive and inconvenient to bring all these patients back to a ward for a 1-2 hour infusion of iron polymaltose after surgery. Other intravenous iron preparations, with similar pharmacological properties, have been shown to be safe when given over similar short periods of time and we believe this will be the case with iron polymaltose too. Some anaesthetists (in Australia and NZ) have already administered iron polymaltose in this manner with no anecdotal reports of any problems, however we believe it warrants formal evaluation.

Study Design and Methods
We aim to recruit 100 patients with iron deficiency anaemia or iron deficiency who are scheduled to undergo general anaesthesia for an elective surgical procedure. Routine care will be unaffected and they will receive general anaesthesia as they would if they were not involved in this trial. Following commencement of surgery and during a period of haemodynamic stability (as assessed by the responsible anaesthetist), they will receive an iron polymaltose infusion over a 10 min period and we will collect data on any adverse effects and change in blood pressure over this time. In order to assess the haemodynamic impact of the infusion, any changes in blood pressure will be compared to the decrease in blood pressure seen at the start of the anaesthetic.

Outcomes
Primary outcome will be the incidence of significant low blood pressure following the administration of iron polymaltose (definition = systolic BP less than 80mmHg or blood pressure treatment required).
Secondary outcomes, will be the incidence of all adverse effects as ascertained by questionnaire 2 hours after surgery and changes in blood markers of iron deficiency.

Potential Benefits / Ethical Issues
The current drug manufacturers product information sheet, recommends a slow infusion of iron polymaltose over approximately 4.5 hours, however most WA hospitals already administer iron polymaltose over a shorter periods of time, with no serious problems.
We believe that if we demonstrate this technique of administration is safe it may lead to more effective & widespread treatment of iron deficiency and anaemia in surgical patients
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34014 0
Address 34014 0
Country 34014 0
Phone 34014 0
Fax 34014 0
Email 34014 0
Contact person for public queries
Name 17261 0
Dr Matthew Harper
Address 17261 0
Department of Anaesthesia
Fremantle Hospital
Level 5 Block
Alma Street
Fremantle
Western Australia 6160
Country 17261 0
Australia
Phone 17261 0
+61 450 832228
Fax 17261 0
Email 17261 0
[email protected]
Contact person for scientific queries
Name 8189 0
Dr Matthew Harper
Address 8189 0
Department of Anaesthesia
Fremantle Hospital
Level 5 Block
Alma Street
Fremantle
Western Australia 6160
Country 8189 0
Australia
Phone 8189 0
+61 450 832228
Fax 8189 0
Email 8189 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.